公开(公告)号：EP1667708B9

公开(公告)日：2012-10-31

申请号：EP03808554.4

申请日：2003-12-23

申请人： Mountain View Pharmaceuticals, Inc.

发明人： SAIFER, Mark G., P. ,  MARTINEZ, Alexa, L. ,  WILLIAMS, David, L. ,  SHERMAN, Merry, R.

IPC分类号： A61K47/48 ,  A61K38/21

CPC分类号： A61K38/215 ,  A61K47/60 ,  C07K14/565 ,  G01N2333/565

公开(公告)号：EP3353329A1

公开(公告)日：2018-08-01

申请号：EP16849780.8

申请日：2016-09-23

申请人： Oklahoma Medical Research Foundation ,  The Board of Trustees of the Leland Stanford Junior University

发明人： AXTELL, Robert, C. ,  STEINMAN, Lawrence

IPC分类号： C12Q1/68 ,  G01N33/53

CPC分类号： G01N33/6896 ,  A61K38/215 ,  G01N33/6863 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2333/565 ,  G01N2800/285 ,  G01N2800/52 ,  G06F19/00 ,  G06F19/18 ,  G06F19/24 ,  G16H50/20 ,  Y02A90/26

摘要： Disclosed herein are methods in which an individual with multiple sclerosis (MS) can be classified into one of six subject groups, each subject group predictive for the patient's responsiveness to an interferon-β (IFN-β) therapy. The individual with MS can be classified according to the individual's serum marker levels, e.g., at baseline or following treatment with therapy. Depending on the classification, the individual with MS can be treated with standard therapies (e.g. IFN-β) or one or more alternative therapies with or without IFN-β.

公开(公告)号：EP2962109A4

公开(公告)日：2016-12-07

申请号：EP14756519

申请日：2014-02-26

申请人： ASTUTE MEDICAL INC

发明人： ANDERBERG JOSEPH ,  GRAY JEFF ,  MCPHERSON PAUL ,  NAKAMURA KEVIN ,  KAMPF JAMES PATRICK

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2333/4724 ,  G01N2333/565 ,  G01N2333/71 ,  G01N2333/90203 ,  G01N2800/347 ,  G01N2800/60

公开(公告)号：EP1667708A4

公开(公告)日：2009-01-14

申请号：EP03808554

申请日：2003-12-23

申请人： MOUNTAIN VIEW PHARMACEUTICALS

发明人： SAIFER MARK G P ,  MARTINEZ ALEXA L ,  WILLIAMS DAVID L ,  SHERMAN MERRY R

IPC分类号： A61K38/21 ,  A61K47/48

CPC分类号： A61K38/215 ,  A61K47/60 ,  C07K14/565 ,  G01N2333/565

公开(公告)号：EP1021726B1

公开(公告)日：2004-12-15

申请号：EP97937333.9

申请日：1997-08-19

申请人： Shaker, Ghassan I.

发明人： MEDENICA, Rajko, D. ,  POWELL, David, K.

IPC分类号： G01N33/68 ,  G01N33/574

CPC分类号： G01N33/5005 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/5044 ,  G01N33/57488 ,  G01N33/68 ,  G01N2333/555 ,  G01N2333/565 ,  Y10S930/142

公开(公告)号：EP3009518A4

公开(公告)日：2017-01-04

申请号：EP14811138

申请日：2014-06-11

申请人： NAT CENTER OF NEUROLOGY AND PSYCHIATRY ,  CHUGAI PHARMACEUTICAL CO LTD

发明人： YAMAMURA TAKASHI ,  NAKAMURA MASAKAZU

IPC分类号： C12Q1/06 ,  A61K39/395 ,  A61K45/00 ,  A61P25/00 ,  C07K16/28 ,  G01N33/50 ,  G01N33/564

CPC分类号： G01N33/564 ,  A61K45/00 ,  C07K16/2866 ,  C07K2317/76 ,  G01N33/5052 ,  G01N2333/5412 ,  G01N2333/565 ,  G01N2333/70596 ,  G01N2800/285 ,  G01N2800/52

摘要： A therapeutic effect of the administration of interferon-² (IFN-²) on a relapsing-remitting multiple sclerosis (RRMS) patient can be predicted and an RRMS case, wherein the administration can be hardly continued because of the occurrence of a serious side effect or worsening of co-occurring immunological disorder, can be predicted by measuring the amount of plasma blasts (PB) in a sample from the RRMS patient. Further, the therapeutic effect of an IL-6 inhibitor in treating RRMS can be predicted by measuring the amount of PB in a sample from an RRMS patient, which enables the provision of a therapeutic method efficacious to a patient to whom IFN-² can be hardly applied in treating RRMS.

公开(公告)号：EP1667708B1

公开(公告)日：2012-06-06

申请号：EP03808554.4

申请日：2003-12-23

申请人： Mountain View Pharmaceuticals, Inc.

发明人： SAIFER, Mark G., P. ,  MARTINEZ, Alexa, L. ,  WILLIAMS, David, L. ,  SHERMAN, Merry, R.

IPC分类号： A61K47/48 ,  A61K38/21

CPC分类号： A61K38/215 ,  A61K47/60 ,  C07K14/565 ,  G01N2333/565

摘要： Methods are provided for the synthesis of polymer conjugates of cytokines and receptor-binding antagonists thereof, especially a non glycosylated interferon-beta, which conjugates retain unusually high biological potency. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-ligand interactions that commonly results from the attachment of polymers to receptor-binding regions of cytokines, as well as to agonistic and antagonistic analogs thereof. The invention also provides conjugates and compositions produced by such methods. The conjugates of the present invention retain a high level of biological potency compared to those produced by traditional polymer coupling methods that are not targeted to avoid receptor-binding domains of cytokines. In assays in vitro, the biological potency of the conjugates of non-glycosylated interferon-beta of the present invention is substantially higher than that of unconjugated interferon-beta and is similar to that of interferon-beta-1a that is glycosylated. The conjugates of the present invention also exhibit an extended half-life in vivo compared to the corresponding unconjugated cytokine. The present invention also provides kits comprising such conjugates and/or compositions, and methods of use of such conjugates and compositions in a variety of diagnostic, prophylactic, therapeutic and bioprocessing applications, including treatment of multiple sclerosis.

摘要翻译： 提供了用于合成细胞因子和其受体结合拮抗剂，特别是非糖基化干扰素-β的聚合物缀合物的方法，所述非糖基化干扰素-β缀合物保持异常高的生物学效力。 根据本发明方法的聚合物缀合物的制备减少或避免了通常由聚合物与细胞因子受体结合区域的连接以及其激动剂和拮抗剂类似物引起的受体 - 配体相互作用的空间抑制。 本发明还提供了通过这种方法生产的缀合物和组合物。 本发明的缀合物与通过传统的聚合物偶联方法产生的那些不是靶向避免细胞因子的受体结合结构域的方法相比，保持了高水平的生物效能。 在体外测定中，本发明的非糖基化干扰素-β的缀合物的生物学效力显着高于未缀合的干扰素-β的结合物，并且与糖基化的干扰素β-1a的相似。 与相应的非缀合细胞因子相比，本发明的缀合物还表现出延长的体内半衰期。 本发明还提供包含此类缀合物和/或组合物的试剂盒，以及在多种诊断，预防，治疗和生物加工应用（包括治疗多发性硬化症）中使用此类缀合物和组合物的方法。

公开(公告)号：EP1667708A2

公开(公告)日：2006-06-14

申请号：EP03808554.4

申请日：2003-12-23

申请人： Mountain View Pharmaceuticals, Inc.

发明人： SAIFER, Mark G., P. ,  MARTINEZ, Alexa, L. ,  WILLIAMS, David, L. ,  SHERMAN, Merry, R.

IPC分类号： A61K38/21

CPC分类号： A61K38/215 ,  A61K47/60 ,  C07K14/565 ,  G01N2333/565

摘要： Methods are provided for the synthesis of polymer conjugates of cytokines and receptor-binding antagonists thereof, especially a non glycosylated interferon-beta, which conjugates retain unusually high biological potency. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-ligand interactions that commonly results from the attachment of polymers to receptor-binding regions of cytokines, as well as to agonistic and antagonistic analogs thereof. The invention also provides conjugates and compositions produced by such methods. The conjugates of the present invention retain a high level of biological potency compared to those produced by traditional polymer coupling methods that are not targeted to avoid receptor-binding domains of cytokines. In assays in vitro, the biological potency of the conjugates of non-glycosylated interferon-beta of the present invention is substantially higher than that of unconjugated interferon-beta and is similar to that of interferon-beta-1a that is glycosylated. The conjugates of the present invention also exhibit an extended half-life in vivo compared to the corresponding unconjugated cytokine. The present invention also provides kits comprising such conjugates and/or compositions, and methods of use of such conjugates and compositions in a variety of diagnostic, prophylactic, therapeutic and bioprocessing applications, including treatment of multiple sclerosis.

公开(公告)号：EP3371332A1

公开(公告)日：2018-09-12

申请号：EP16863089.5

申请日：2016-11-04

申请人： Mayo Foundation for Medical Education and Research

发明人： MUSKARDIN, Theresa L. Wampler ,  NIEWOLD, Timothy B.

IPC分类号： C12Q1/68 ,  G01N33/53 ,  G01N33/68

CPC分类号： G01N33/564 ,  A61K31/519 ,  C07K16/2878 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/6866 ,  G01N2333/525 ,  G01N2333/5421 ,  G01N2333/545 ,  G01N2333/56 ,  G01N2333/565 ,  G01N2800/102 ,  G01N2800/52

摘要： This document provides methods and materials involved in treating autoimmune conditions. For example, methods and materials for using either (a) one or more tumor necrosis factor alpha (TNF-α) inhibitors or (b) one or more Janus kinase (JAK) inhibitors to treat autoimmune conditions such as rheumatoid arthritis are provided.

公开(公告)号：EP2962109A1

公开(公告)日：2016-01-06

申请号：EP14756519.6

申请日：2014-02-26

申请人： Astute Medical, Inc.

发明人： ANDERBERG, Joseph ,  GRAY, Jeff ,  MCPHERSON, Paul ,  NAKAMURA, Kevin ,  KAMPF, James, Patrick

IPC分类号： G01N33/566

CPC分类号： G01N33/6893 ,  G01N2333/4724 ,  G01N2333/565 ,  G01N2333/71 ,  G01N2333/90203 ,  G01N2800/347 ,  G01N2800/60

摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor X, Coagulation factor V, soluble Receptor tyrosine- protein kinase erbB-2, Interferon beta, C-type lectin domain family 11 member A, Glyceraldehyde- 3 -phosphate dehydrogenase, Interferon omega- 1, Coagulation factor VIII, Thrombin- Antithrombin- III complex, and soluble Tumor necrosis factor ligand superfamily member 13B as diagnostic and prognostic biomarkers in renal injuries.

摘要翻译： 本发明涉及用于监测，诊断，预后和确定患有或怀疑患有肾损伤的受试者的治疗方案的方法和组合物。 具体而言，本发明涉及使用一种或多种配置为检测选自由凝血因子X，凝血因子V，可溶性受体酪氨酸 - 蛋白激酶erbB-2，干扰素β，C型组成的组的肾损伤标志物的测定 凝集素结构域家族11成员A，甘油醛-3-磷酸脱氢酶，干扰素ω-1，凝血因子VIII，凝血酶 - 抗凝血酶-III复合物和可溶性肿瘤坏死因子配体超家族成员13B作为肾损伤中的诊断和预后生物标志物。